secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0000950170-24-069674
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics announces Pfizer collaboration and three new pipeline programs
--------------------------------------------------------------------------------

- Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.
- New pre-clinical programs: vascular malformations, Fabry disease non-inhibitory chaperone, and NRAS-selective inhibitor, targeting over 200,000 U.S. patients.
- RLY-2608 clinical development in vascular malformations expected Q1 2025; Fabry disease chaperone and NRAS inhibitor to enter clinic in H2 2025.
- Cash runway guidance unchanged; $750 million expected to fund operations into second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/0000950170-24-069674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/rlay-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-069674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer